NCT04482933 2026-02-10
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
Phase 2 Withdrawn
Clinical Trials
234 trialsNCT06012929 2026-01-26
A Study of ONC201 for Refractory Meningioma
University of Nebraska
Phase 2 Withdrawn
NCT06163664 2026-01-13
Role of ChatGPT in Vestibular Schwannoma Management
University of Southern California
Phase NA Withdrawn
NCT06466798 2026-01-08
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
The University of Texas Health Science Center, Houston
Phase 1 Withdrawn
NCT03261726 2025-12-19
Maintaining Cochlear Patency After VIIIth Nerve Surgery
Henry Ford Health System
Phase NA Withdrawn
NCT05669326 2025-12-03
NODDI-TRACT
GCS Ramsay Santé pour l'Enseignement et la Recherche
Phase NA Withdrawn
NCT06776406 2025-11-25
Head Stabilization in Whole Brain RT
Abramson Cancer Center at Penn Medicine
Phase NA Withdrawn
NCT05904704 2025-11-14
Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors
OHSU Knight Cancer Institute
Phase NA Withdrawn
NCT05341947 2025-10-22
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Withdrawn
NCT05720624 2025-10-22
Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
Mayo Clinic
Phase 1 Withdrawn
NCT03974204 2025-09-26
Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.
Centre Oscar Lambret
Phase NA Withdrawn
NCT04500548 2025-09-10
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05789862 2025-08-29
Behavioral Health Evaluation and Intervention Program for Patients Undergoing Craniotomy
University of California, San Francisco
Phase NA Withdrawn
NCT07011849 2025-08-13
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04118036 2025-08-11
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06501911 2025-07-22
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
University of Nebraska
Phase 1 Withdrawn
NCT04838782 2025-07-08
Role of Repeat Resection in Recurrent Glioblastoma
University of Alberta
Phase NA Withdrawn
NCT07046481 2025-07-01
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
Region Skane
Phase NA Withdrawn
NCT05620914 2025-06-15
PARAMETer
Duke University
Phase 2 Withdrawn
NCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT05927610 2025-05-21
Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Withdrawn
NCT02145910 2025-05-02
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Thomas Jefferson University
Phase 1 Withdrawn
NCT04667715 2025-05-02
BBBD
InSightec
Phase NA Withdrawn
NCT04196933 2025-04-16
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
Massachusetts Eye and Ear Infirmary
Phase NA Withdrawn
NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
NCT05516485 2025-03-04
Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
University of Southern California
Phase NA Withdrawn
NCT06233903 2025-01-21
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2 Withdrawn
NCT06308575 2025-01-10
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06463184 2024-12-04
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT05879120 2024-11-20
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04521946 2024-10-26
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03990597 2024-10-09
StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05773664 2024-09-19
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT03925675 2024-09-03
18F-Fluciclovine PET and Multiparametric MR Imaging
Loma Linda University
Phase 2 Withdrawn
NCT06182410 2024-08-07
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
University of California, San Francisco
Phase 2 Withdrawn
NCT06335745 2024-08-05
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
Dana-Farber Cancer Institute
Phase NA Withdrawn
NCT05082493 2024-06-06
A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
WPD Pharmaceuticals Sp. z o.o.
Phase 1 Withdrawn
NCT05999357 2024-05-29
STRIDER
Maastricht University Medical Center
Phase 2 Withdrawn
NCT03955068 2024-05-22
Strict Classic Ketogenic Diet as a Therapy for Recurrent or Progressive and Refractory Brain Tumors in Children
University of Texas Southwestern Medical Center
Phase NA Withdrawn
NCT01622764 2024-05-06
89Zr-RO5323441 PET Imaging in Glioblastoma
University Medical Center Groningen
Phase 2 Withdrawn
NCT05120960 2024-04-17
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT06137651 2024-04-01
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Northwestern University
Phase 1 Withdrawn
NCT05952687 2024-03-27
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
St. Jude Children's Research Hospital
Phase 1 Withdrawn
NCT05666349 2024-03-26
RiNG
University College, London
Phase 1 Withdrawn
NCT03935269 2024-03-20
CERESET
Wake Forest University Health Sciences
Phase NA Withdrawn
NCT05672082 2024-02-08
INFLAGLI
Center Eugene Marquis
Phase NA Withdrawn
NCT05373381 2024-02-02
The KetoGlioma (Ketogenic Glioma) Study
Tufts Medical Center
Phase NA Withdrawn
NCT04218019 2024-01-05
GERAS
University Hospital Heidelberg
Phase NA Withdrawn